Abstract
BackgroundOmentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. Recent studies indicate a paradoxical relationship between adiponectin and cardiovascular mortality across many clinical settings including type 2 diabetes. In this study, we characterized the clinical features of type 2 diabetes patients with increased adiponectin levels and examined the association between omentin and atherosclerosis in those patients.MethodsThe subjects were 413 patients with type 2 diabetes. Fasting plasma omentin and total adiponectin levels were measured by enzyme-linked immunosorbent assay. The intima-media thickness (IMT) of the common carotid artery was measured by ultrasonography. The subjects were stratified according to the median value of plasma adiponectin.ResultsIn high-adiponectin group, omentin levels were higher, while IMT tended to be greater than those in low-adiponectin group. The high-adiponectin group also exhibited older age, higher systolic blood pressure, lower kidney function, body mass index, and insulin resistance index compared to the low-adiponectin group. Multivariate analysis revealed that omentin levels were independently and negatively associated with IMT in high-adiponectin group, but not in low-adiponectin group, after adjusting for adiponectin levels and traditional cardiovascular risk factors. On the other hand, adiponectin levels were not significantly associated with IMT in either group.ConclusionsPlasma omentin levels are inversely associated with IMT in type 2 diabetes patients with increased adiponectin levels and multiple cardiovascular risk factors. This study suggests a protective role of omentin against atherosclerosis in type 2 diabetes patients, which is potentially influenced by adiponectin level and cardiovascular risk status.
Highlights
Omentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders
In the present study, we investigated the clinical features of type 2 diabetes (T2D) patients showing increased plasma adiponectin levels and the relationship between plasma omentin levels and carotid intima-media thickness (IMT) in those patients
Our results demonstrated that the high-adiponectin group had increased omentin levels, multiple cardiovascular disease (CVD) risk factors, and non-significantly greater IMT, as compared to the low-adiponectin group of T2D patients
Summary
Omentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. We reported that plasma omentin levels were higher in T2D patients than healthy controls and were positively associated with flow-mediated vasodilatation, a marker of endothelial function, in high-risk subgroups of T2D patients with older age, reduced kidney function, or preexisting cardiovascular diseases (CVDs) [16] Those prior studies [6, 9,10,11,12,13,14], including ours [16], suggest a protective role of human omentin on atherosclerotic CVDs. Adiponectin is well-recognized as an anti-inflammatory adipocytokine which exerts beneficial actions on metabolic and cardiovascular disorders [8, 17, 18]. These clinical findings collectively suggest that adiponectin fails to exert its protective effect against atherosclerotic CVDs in individuals with T2D
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
